For instance, preliminary results from selective RET inhibitors have shown impressive results in lung cancer and MTC [288] However, the use of highly selective TKIs does not always lead to tumor response, and even when it does, a considerable number of patients relapse due to the appearance of acquired resistance mutations. Here, RET is linked to medullary thyroid gland carcinoma.